QC
HRMY icon

Quadrature Capital’s Harmony Biosciences HRMY Stock Holding History

Quadrature Capital’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$545K Sell
14,958
-20,173
-57% -$636K ﹤0.01% 980
2026
Q1 		$984K Buy
35,131
+10,580
+43% +$347K 0.01% 563
2025
Q4 		$919K Buy
+24,551
New +$807K 0.01% 539

Other funds holding HRMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Quadrature Capital's HRMY Position: Q2 2026 in Review

Quadrature Capital reduced its Harmony Biosciences (HRMY) stake by 57% in Q2 2026, selling an estimated $636K and leaving 14,958 shares worth $545K. The position accounts for ﹤0.01% of the portfolio, ranked #980.

Quadrature Capital first reported a position in HRMY in Q4 2025 and has held it in 3 quarters since. The position peaked at $984K in Q1 2026. 327 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

  • Quadrature Capital held 14,958 shares of Harmony Biosciences worth $545K as of Q2 2026.
  • Quadrature Capital sold 20,173 Harmony Biosciences shares in Q2 2026, an estimated $636K.
  • Harmony Biosciences made up ﹤0.01% of Quadrature Capital's portfolio in Q2 2026, its #980 holding.
  • Quadrature Capital first reported a position in Harmony Biosciences in Q4 2025 and has held it in 3 quarters since.
  • Quadrature Capital's Harmony Biosciences position peaked at $984K in Q1 2026.
  • 327 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.